Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
James Lp's research focuses on the development and validation of analytical methods for substance abuse detection and the study of drug pharmacokinetics. He has received significant federal funding to support these endeavors. Lp is a Principal Investigator on two NIH grants totaling over $4.4 million. The first, "Expanding Translational Research in Arkansas," funded by the National Center for Advancing Translational Sciences, received $4,269,045. The second, "Expanding Translational Science in Arkansas," funded by the NIH Office of the Director, received $214,200. These grants underscore his role in advancing translational research within Arkansas.
His recent publications include work on the external evaluation of a population pharmacokinetics model for meropenem in infants and the validation of ToxBox kits for automating LC-MS/MS analyses of emerging drug threats. These publications highlight his expertise in analytical chemistry, mass spectrometry, and pharmacokinetics, particularly in the context of drug detection and quantification. Lp collaborates with researchers at the University of Arkansas for Medical Sciences, including William E. Fantegrossi, Jeffery H. Moran, and Marina Avram, contributing to a shared publication record.
Metrics
- h-index: 1
- Publications: 4
- Citations: 14
Selected Publications
-
External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants. (2026)
-
Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses (2026)
-
Impaired Driving Associated with the Synthetic Cannabinoid 5F-ADB (2018)
Federal Grants 2 $8,092,234 total
Collaboration Network
Top Collaborators
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.
- External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.
- External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.
- External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.
- External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.
Similar Researchers
Based on overlapping research topics